Product Name: N-terminal pro brain natriuretic peptide (NT-proBNP) detection kit (Magnetic Solid Phase Chemiluminescent Immunoassay)
Packaging:
24 T/KIT
Intended Use:
This product is used for the in vitro quantitative determination of NT-proBNP in human serum, plasma or whole blood samples, and is mainly used clinically as an aid in the diagnosis of heart failure.
Heart failure is an important clinical syndrome that compromises either left ventricular systolic or diastolic function or both.
BNP is a member of the structurally identical natriuretic peptide family, which includes atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and urodilatin. The secretion of ANP and BNP is a product of atrial and ventricular secretion, with the majority of BNP being secreted primarily by the left ventricle from the precursor protein (proBNP), which is cleaved into the active BNP and the inactive NT-proBNP. Plasma ANP and BNP are elevated in a variety of pathological states, particularly in conditions of increased ventricular wall tension, increased circulating volume (e.g., heart failure, renal failure, increased aldosterone, etc.), or decreased natriuretic peptide clearance (e.g., renal failure). However, BNP secretion is controlled by metabolic levels and usually requires a longer period of stimulation. Plasma BNP concentrations are elevated in patients with heart failure, and the degree of BNP elevation corresponds to New York Heart Association (NYHA) classification.